GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mercury Biopharmaceutical Corp (ROCO:6932) » Definitions » EBITDA Margin %

Mercury Biopharmaceutical (ROCO:6932) EBITDA Margin % : -11,223.17% (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Mercury Biopharmaceutical EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Mercury Biopharmaceutical's EBITDA for the six months ended in Dec. 2024 was NT$-27.61 Mil. Mercury Biopharmaceutical's Revenue for the six months ended in Dec. 2024 was NT$0.25 Mil. Therefore, Mercury Biopharmaceutical's EBITDA margin for the quarter that ended in Dec. 2024 was -11,223.17%.


Mercury Biopharmaceutical EBITDA Margin % Historical Data

The historical data trend for Mercury Biopharmaceutical's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mercury Biopharmaceutical EBITDA Margin % Chart

Mercury Biopharmaceutical Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBITDA Margin %
Get a 7-Day Free Trial - - -1,048.62 -3,778.70 -851.78

Mercury Biopharmaceutical Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -2,167.38 -310.90 -11,223.17

Competitive Comparison of Mercury Biopharmaceutical's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Mercury Biopharmaceutical's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mercury Biopharmaceutical's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mercury Biopharmaceutical's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Mercury Biopharmaceutical's EBITDA Margin % falls into.


;
;

Mercury Biopharmaceutical EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Mercury Biopharmaceutical's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-42.274/4.963
=-851.78 %

Mercury Biopharmaceutical's EBITDA Margin % for the quarter that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-27.609/0.246
=-11,223.17 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mercury Biopharmaceutical  (ROCO:6932) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Mercury Biopharmaceutical EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Mercury Biopharmaceutical's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Mercury Biopharmaceutical Business Description

Traded in Other Exchanges
N/A
Address
No. 653-1, Bannan Road, 15th Floor, Zhonghe District, New Taipei City, TWN
Mercury Biopharmaceutical Corp focuses on the development of drugs for unmet medical needs. It offers a development platform focusing on rapid release and free adjustable doses. Its 3D powder bonding method (binder jetting) combines powder and special molding adhesive and stacks them in layers.

Mercury Biopharmaceutical Headlines

No Headlines